Assessment of CafA Targeted BAR-Encapsulated Nanoparticles against Oral Biofilms.

Bibliographic Details
Title: Assessment of CafA Targeted BAR-Encapsulated Nanoparticles against Oral Biofilms.
Authors: Desai, Hetal, Mahmoud, Mohamed Y., Tan, Jinlian, Minooei, Farnaz, Demuth, Donald R., Steinbach-Rankins, Jill M.
Source: Pharmaceutics; Sep2020, Vol. 12 Issue 9, p835, 1p
Subject Terms: PORPHYROMONAS gingivalis, BIOFILMS, PERIODONTAL disease, NANOPARTICLES, MOIETIES (Chemistry), ACTINOMYCES
Abstract: Porphyromonas gingivalis adherence to Streptococcus gordonii is a crucial initial event that facilitates the colonization of P. gingivalis, a key pathogen in periodontal disease. As such, blocking these early interactions may present a potential avenue to limit P. gingivalis colonization. Nanoparticles encapsulating a synthetic peptide BAR (BAR-encapsulated NPs) inhibit P. gingivalis/S. gordonii biofilm formation 1.8-fold more potently relative to free BAR. However, BAR-encapsulated NPs, like many orally delivered formulations, may benefit from a strategy that improves their retention in an open flow environment. Here, we sought to enhance the efficacy of BAR-encapsulated NPs by modifying their surfaces with coaggregation factor A (CafA), a fimbrial protein expressed by the early colonizer, Actinomyces oris. We demonstrate that the targeting moiety, CafA, enhances NP binding and exhibits specificity of adherence to S. gordonii, relative to other oral bacterial species. Furthermore, CafA-modified NPs release inhibitory concentrations of BAR for 12 h, a time frame relevant to oral dosage form delivery. Lastly, CafA-modified NPs potently inhibit P. gingivalis/S. gordonii biofilm formation for up to 12 h and are non-toxic at therapeutically-relevant concentrations. These results suggest that CafA-modified NPs represent a novel and efficacious delivery vehicle for localized, targeted delivery of BAR to P. gingivalis preferred niches. [ABSTRACT FROM AUTHOR]
Copyright of Pharmaceutics is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Complementary Index
Full text is not displayed to guests.
More Details
ISSN:19994923
DOI:10.3390/pharmaceutics12090835
Published in:Pharmaceutics
Language:English